The DOI matches its Crossref record; 323 of the 323 references it cites were found in a registry or an index.
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
Abstract
With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes an overwhelming health, social, economic, and political problem to nations. Unless a new medicine capable to delay disease progression is found, the number of cases will reach 107 million in 2050. So far, the therapeutic paradigm one‐compound‐one‐target has failed. This could be due to the multiple pathogenic mechanisms involved in AD including amyloid β (Aβ) aggregation to form plaques, τ hyperphosphorylation to disrupt microtubule to form neurofibrillary tangles, calcium imbalance, enhanced oxidative stress, impaired mitochondrial function, apoptotic neuronal death, and deterioration of synaptic transmission, particularly at cholinergic neurons. Approximately 100 compounds are presently been investigated directed to single targets, namely inhibitors of β and γ secretase, vaccines or antibodies that clear Aβ, metal chelators to inhibit Aβ aggregation, blockers of glycogen synthase kinase 3β, enhancers of mitochondrial function, antioxidants, modulators of calcium‐permeable channels such as voltage‐dependent calcium channels,N‐methyl‐D‐aspartate receptors for glutamate, or enhancers of cholinergic neurotransmission such as inhibitors of acetylcholinesterase or butyrylcholinesterase. In view of this complex pathogenic mechanisms, and the successful treatment of chronic diseases such as HIV or cancer, with multiple drugs having complementary mechanisms of action, the concern is growing that AD could better be treated with a single compound targeting two or more of the pathogenic mechanisms leading to neuronal death. This review summarizes the current therapeutic strategies based on the paradigm one‐compound‐various targets to treat AD. A treatment that delays disease onset and/or progression by 5 years could halve the number of people requiring institutionalization and/or dying from AD. © 2011 Wiley Periodicals, Inc. Med Res Rev
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–323 of 323
Mary, A., Renko, D. Z., Guillou, C., & Thal, C. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00133-3 · Cited by 108
Dimeric and Hybrid Anti-Alzheimer Drug Candidates
Munoz-Torrero, D., & Camps, P. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706775527974 · Cited by 107
Werling, L. L., Keller, A. B., Frank, J. G., & Nuwayhid, S. J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.013 · Cited by 107
Multiple Central Nervous System Targets for Eliciting Beneficial Effects on Memory and Cognition
Buccafusco, J. J., & Terry, A. V. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38924-4 · Cited by 107
Satpute‐Krishnan, P., DeGiorgis, J. A., & Bearer, E. L. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00069.x · Cited by 106
Disease-Modifying Therapies in Alzheimer???s Disease: How Far Have We Come?
ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 106
Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs
Martínez, A. (2008) · Medicinal Research Reviews · doi:10.1002/med.20119 · Cited by 104
SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task
Wolff, M. C., & Leander, J. D. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.025 · Cited by 103
Rogawski, M. A. (2000) · Amino Acids · doi:10.1007/s007260070042 · Cited by 103
Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease
Petersen, R. B., Nunomura, A., Lee, H., Casadesús, G., Perry, G. L., Smith, M. A., & Zhu, X. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11202 · Cited by 101
Kurt, M. A., Davies, D. C., Kidd, M., Duff, K., Rolph, S. C., JENNINGS, K. H., & Howlett, D. R. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7717 · Cited by 101
Development of BACE1 Inhibitors for Alzheimers Disease
Guo, T., & Hobbs, D. W. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777452489 · Cited by 101
Li, W., Pi, R., Chan, H. H. N., Fu, H., Lee, N. T. K., Tsang, H. W., Pu, Y., Chang, D. C., Li, Z., Luo, J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411085200 · Cited by 100
VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux
Mohler, E. G., Shacham, S., Noiman, S., Lezoualc’h, F., Robert, S. J., Gastineau, M., Rutkowski, J., Marantz, Y., Dumuis, A., Bockaert, J., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.016 · Cited by 99
Apolipoprotein E and β‐amyloid (1–42) regulation of glycogen synthase kinase‐3β
Cedazo-Mínguez, Á., Popescu, B. O., Blanco‐Millán, J. M., Akterin, S., Pei, J. ‐., Winblad, B. G., & Cowburn, R. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02088.x · Cited by 99
Cannabinoids and Memory; Animal Studies
Castellano, C., Rossi‐Arnaud, C., Cestari, V., & Costanzi, M. (2003) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007033482670 · Cited by 97
Pollard, H. B., Rojas, E., & Arispe, N. J. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb23046.x · Cited by 96
Ghosh, A. K., Kumaragurubaran, N., Lin, H., Kulkarni, S. S., Xu, X., Miller, H. B., Reddy, D. S., Weerasena, V., Turner, R. T., Chang, W., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.028 · Cited by 96
From large networks to small molecules
Sharom, J. R., Bellows, D. S., & Tyers, M. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.12.007 · Cited by 96
Bis(7)‐tacrine attenuates β amyloid‐induced neuronal apoptosis by regulating L‐type calcium channels
Fu, H., Li, W., Lao, Y., Luo, J., Lee, N. T. K., Kan, K. K. W., Tsang, H. W., Tsim, K. W. K., Pang, Y., Li, Z., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03960.x · Cited by 95
Treatment of Alzheimer's disease: current and future therapeutic approaches.
Cummings, J. L. (2004) · PubMed · Cited by 94
Fisher, A. (2008) · Neurodegenerative Diseases · doi:10.1159/000113712 · Cited by 94
Induction of Quinone Reductase as a Primary Screen for Natural Product Anticarcinogens
Kang, Y., & Pezzuto, J. M. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82021-4 · Cited by 92
Melatonin attenuates amyloid beta25–35-induced apoptosis in mouse microglial BV2 cells
Jang, M.-H., Jung, S.-B., Lee, M., Kim, C., Oh, Y.-T., Kang, I., Kim, J., & Kim, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.01.003 · Cited by 92
Marco, J. L., Rı́os, C. D. L., Garcı́a, A. G., Villarroya, M., Carreiras, M. C., Martins, C., Eleutério, A., Morreale, A., Orozco, M., & Luque, F. J. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.02.017 · Cited by 91
Wong, D. M., Greenblatt, H. M., Dvir, H., Carlier, P. R., Han, Y., Pang, Y., Silman, I., & Sussman, J. L. (2002) · Journal of the American Chemical Society · doi:10.1021/ja021111w · Cited by 90
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for alzheimer’s disease
Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 89
Kontoghiorghes, G. J. (1995) · The Analyst · doi:10.1039/an9952000845 · Cited by 89
Guillou, C., Mary, A., Renko, D. Z., Gras, E., & Thal, C. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00059-7 · Cited by 88
Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz‐Torrero, D., Ramírez, L., Viayna, E., Gómez, E., Isambert, N., Lavilla, R., et al. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.02.013 · Cited by 87
CB1 Receptor Antagonism Increases Hippocampal Acetylcholine Release: Site and Mechanism of Action
Degroot, A., Köfalvi, A., Wade, M. R., Davis, R. J., Rodrigues, R. J., Rebola, N., Cunha, R. A., & Nomikos, G. G. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024661 · Cited by 85
Discovery of Oxadiazoyl Tertiary Carbinamine Inhibitors of β-Secretase (BACE-1)
Rajapakse, H. A., Nantermet, P. G., Selnick, H. G., Munshi, S. K., McGaughey, G. B., Lindsley, S. R., Young, M. B., Lai, M., Espeseth, A. S., Shi, X., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061046r · Cited by 84
Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Bona, D. D., Scapagnini, G., Candore, G., Castiglia, L., Colonna‐Romano, G., Duro, G., Nuzzo, D., Iemolo, F., Lio, D., Pellicanò, M., et al. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790883769 · Cited by 84
Piazzi, L., Cavalli, A., Belluti, F., Bisi, A., Gobbi, S., Rizzo, S., Bartolini, M., Andrisano, V., Recanatini, M., & Rampa, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070100g · Cited by 82
Melchiorre, C., Andrisano, V., Bolognesi, M. L., Budriesi, R., Cavalli, A., Cavrini, V., Rosini, M., Tumiatti, V., & Recanatini, M. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810452 · Cited by 81
Xie, Q., Wang, H., Xia, Z., Lu, M., Zhang, W., Wang, X., Fu, W., Tang, Y., Sheng, W., Li, W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070154q · Cited by 80
Crouch, P. J., White, A. R., & Bush, A. I. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05918.x · Cited by 78
Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors
Carlier, P. R., Du, D., Han, Y., Liu, J., & Pang, Y. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00396-0 · Cited by 77
Shao, D., Zou, C., Luo, C., Tang, X.-C., & Li, Y. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.07.005 · Cited by 75
Hanessian, S., Yun, H., Hou, Y., Yang, G., Bayrakdarian, M., Therrien, É., Moitessier, N., Roggo, S. P., Veenstra, S. J., Tintelnot‐Blomley, M., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050142+ · Cited by 74
Leon, R. M., Ríos, C. D. L., Marco, J. L., Huertas, Ó., Barril, X., Luque, F. J., López, M. G., García, A. G., & Villarroya, M. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.005 · Cited by 74
Sills, M. A., & Loo, P. S. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)00612-1 · Cited by 73
Bolognesi, M. L., Cavalli, A., Bergamini, C., Fato, R., Lenaz, G., Rosini, M., Bartolini, M., Andrisano, V., & Melchiorre, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901123n · Cited by 73
Cavalli, A., Bottegoni, G., Raco, C., Vivo, M. D., & Recanatini, M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040787u · Cited by 72
Fresh Evidence Points to an Old Suspect: Calcium
Marx, J. (2007) · Science · doi:10.1126/science.318.5849.384 · Cited by 71
Kogen, H., Toda, N., Tago, K., Marumoto, S., Takami, K., Ori, M., Yamada, N., Koyama, K., Naruto, S., Abe, K., et al. (2002) · Organic Letters · doi:10.1021/ol026418e · Cited by 71
Inestrosa, N., Alvarez, A. R., & Calderón, F. H. (1996) · PubMed · Cited by 71
Mitsui, H., Takuwa, N., Maruyama, T., Maekawa, H., Hirayama, M., Sawatari, T., Hashimoto, N., Takuwa, Y., & Kimura, S. (2001) · International Journal of Cancer · Cited by 70
MAO inhibitors and oxidant stress in aging brain tissue
Alper, G. E., Girgin, F. K., Özgönül, M., Menteş, G., & Ersöz, B. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00035-2 · Cited by 70
Effect of Desferrioxamine and D.T.P.A. in Iron Overload
Bannerman, R. M., Callender, S. T., & Williams, D. L. (1962) · BMJ · doi:10.1136/bmj.2.5319.1573 · Cited by 69
Fu, Li, Lao, Luo, Lee, Nt, Kan, K., kk, K., Tsang, Hw, et al. (2006) · 中国生物学文摘 · Cited by 68
Rampa, A., Piazzi, L., Belluti, F., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010914b · Cited by 67
Pharmacologic treatment of cognition in Alzheimer's dementia
Farlow, M. R., & Evans, R. M. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s36 · Cited by 64
Kwon, Y. E., Park, J. Y., No, K. T., Shin, J. H., Lee, S. K., Eun, J. S., Yang, J. H., Shin, T. Y., Kim, D. K., Chae, B. S., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.07.003 · Cited by 64
Purification of CK1 by affinity chromatography on immobilised axin
Reinhardt, J., Ferandin, Y., & Meijer, L. (2007) · Protein Expression and Purification · doi:10.1016/j.pep.2007.02.020 · Cited by 64
Lange, J. H. M., Coolen, H. K. A. C., van der Neut, M. A. W., Borst, A. J. M., Stork, B., Verveer, P. C., & Kruse, C. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901614b · Cited by 64
Yang, D., Soulier, J. L., Sicsic, S., Mathé‐Allainmat, M., Brémont, B., Croci, T., Cardamone, R., Aureggi, G., & Langlois, M. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960320m · Cited by 64
Veroff, A. E., Bodick, N. C., Offen, W., Sramek, J. J., & Cutler, N. R. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199812000-00010 · Cited by 64
Choi, R. C. Y., Zhu, J., Leung, K. W., Chu, G. K. Y., Xie, H. Q., Chen, V. P., Zheng, Y., Lau, D. T. W., Dong, T. T.-X., Chow, P. C. Y., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1293 · Cited by 63
Pharmacotherapeutic targets in Alzheimer's disease
Biran, Y., Masters, C. L., Barnham, K. J., Bush, A. I., & Adlard, P. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00595.x · Cited by 63
Marco, J. L., Rı́os, C. D. L., Carreiras, M. C., Baños, J.-E., Badı́a, A., & Vivas, N. M. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00284-4 · Cited by 63
Fu, H., Li, W., Luo, J., Lee, N. T. K., Li, M., Tsim, K. W. K., Pang, Y., Youdim, M. B. H., & Han, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.068 · Cited by 62
Spuch, C., Antequera, D., Fernández‐Bachiller, M. I., Rodrı́guez-Franco, M. I., & Carro, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9121-2 · Cited by 62
Bar‐Am, O., Weinreb, O., Amit, T., & Youdim, M. B. H. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9139-6 · Cited by 60
γ-Secretase: a complex target for Alzheimer's disease
Lundkvist, J., & Näslund, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.002 · Cited by 59
Xiao, X. Q., Lee, N. T. K., Carlier, P. R., Pang, Y., & Han, Y. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01357-4 · Cited by 59
Tumiatti, V., Milelli, A., Minarini, A., Rosini, M., Bolognesi, M. L., Micco, M., Andrisano, V., Bartolini, M., Mancini, F., Recanatini, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8009684 · Cited by 58
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Shanks, M. F., Kivipelto, M., Bullock, R. A., & Lane, R. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903209332 · Cited by 58
Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors
Cumming, J. N., Le, T. X., Babu, S. K. G., Carroll, C. D., Chen, X., Favreau, L. V., Gaspari, P. M., Guo, T., Hobbs, D., Huang, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.050 · Cited by 58
Bembenek, S. D., Keith, J. M., Letavic, M. A., Apodaca, R. L., Barbier, A., Dvorak, L. K., Aluisio, L. E., Miller, K. L., Lovenberg, T. W., & Carruthers, N. I. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.12.048 · Cited by 57
Novel modulators of amyloid‐β precursor protein processing
Tang, B. L., & Liou, Y. C. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04215.x · Cited by 57
Bragin, V., Chemodanova, M., Dzhafarova, N., Bragin, I., Czerniawski, J. L., & Aliev, G. M. (2005) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750502000103 · Cited by 56
Mancini, F., Naldi, M., Cavrini, V., & Andrisano, V. (2007) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-007-1356-2 · Cited by 54
Synthesis, acetylcholinesterase inhibition and neuroprotective activity of new tacrine analogues
Leon, R. M., Marco, J. L., Garcı́a, A. G., & Villarroya, M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.11.020 · Cited by 54
Novel tacrine derivatives that block neuronal calcium channels
Rı́os, C. D. L. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00378-9 · Cited by 54
Proceedings of the British Pharmacological Society
Towart, R., & Kazda, S. (1979) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1979.tb08695.x · Cited by 53
Engelberts, I., von Asmuth, E. J., van der Linden, J., & Buurman, W. A. (1991) · PubMed · Cited by 52
Gandy, S., & Greengard, P. (1994) · International review of neurobiology · doi:10.1016/s0074-7742(08)60302-5 · Cited by 52
Zheng, H., Youdim, M. B. H., & Fridkin, M. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100069c · Cited by 52
New multipotent tetracyclic tacrines with neuroprotective activity
Marco, J. L., Leon, R. M., Rı́os, C. D. L., Garcı́a, A. G., López, M. G., & Villarroya, M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.025 · Cited by 51
Yang, W., Lu, W., Lu, Y., Zhong, M., Sun, J., Thomas, A. E., Wilkinson, J. M., Fucini, R. V., Lam, M. B., Randal, M., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0509142 · Cited by 51
Szuromi, P., Vinson, V. J., & Marshall, E. (2004) · Science · doi:10.1126/science.303.5665.1795 · Cited by 49
Kozikowski, A., Nowak, I., Petukhov, P., Etcheberrigaray, R., Mohamed, A., Tan, M., Lewin, N., Hennings, H., Pearce, L. L., & Blumberg, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020350r · Cited by 48
Marco, J. L., Leon, R. M., López, M. G., Garcı́a, A. G., & Villarroya, M. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.06.016 · Cited by 48
Systematic Review on the Efficacy and Safety of Herbal Medicines for Alzheimer's Disease
Man, S. C., Durairajan, S. S. K., Kum, W. F., Lu, J., Huang, J. D., Cheng, C. F., Chung, V. C., Xu, M., & Li, M. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14209 · Cited by 46
Fang, L., Jumpertz, S., Zhang, Y., Appenroth, D., Fleck, C., Mohr, K., Tränkle, C., & Decker, M. W. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901616h · Cited by 45
Lipoic Acid, a Lead Structure for Multi-Target-Directed Drugs for Neurodegeneration
Bolognesi, M. L., Minarini, A., Tumiatti, V., & Melchiorre, C. (2006) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955706778742731 · Cited by 44
Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer's therapy
Storr, T., Scott, L. E., Bowen, M. L., Green, D. E., Thompson, K. H., Schugar, H. J., & Orvig, C. (2009) · Dalton Transactions · doi:10.1039/b902545f · Cited by 44
Kozikowski, A. P., Chen, Y., Tapadar, S., Lewin, N. E., Blumberg, P. M., Zhong, Z., D’Annibale, M. A., Wang, W., Shen, Y., & Langley, B. C. (2009) · ChemMedChem · doi:10.1002/cmdc.200900045 · Cited by 43
Liu, J., Ho, W. L., Lee, N. T. K., Carlier, P. R., Pang, Y., & Han, Y. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00905-8 · Cited by 43
Jammal, A. E., Howell, P. L., Turner, M. A., Li, N., & Templeton, D. M. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00030a005 · Cited by 43
Toda, N., Kaneko, T., & Kogen, H. (2010) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.58.273 · Cited by 42
Toda, N., Tago, K., Marumoto, S., Takami, K., Ori, M., Yamada, N., Koyama, K., Naruto, S., Abe, K., Yamazaki, R., et al. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00091-9 · Cited by 40
Amitriptyline Is a Potent Blocker of Human Kv1.1 and Kv7.2/7.3 Channels
Punke, M. A., & Friederich, P. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000260310.63117.a2 · Cited by 40
Iodinated tracers for imaging amyloid plaques in the brain
Kung, H. F. (2003) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2003.09.003 · Cited by 39
Fink, D. M., Palermo, M. G., Bores, G. M., Huger, F. P., Kurys, B. E., Merriman, M. C., Olsen, G. E., Petko, W. W., & O'Malley, G. J. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00072-8 · Cited by 37
Hieke, M., Neß, J., Steri, R., Dittrich, M., Greiner, C., Werz, O., Baumann, K., Schubert‐Zsilavecz, M., Weggen, S., & Zettl, H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1003073 · Cited by 37
Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders
Alguacil, L. F., & Pérez‐García, C. (2003) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007033482760 · Cited by 35
Neuroprotective activities of carvedilol and a hydroxylated derivative
Lysko, P. G., Lysko, K. A., Webb, C. L., Feuerstein, G., Mason, P. E., Walter, M. F., & Mason, R. P. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00275-5 · Cited by 34
Takashima, A. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r29fm · Cited by 34
Dillen, K., & Annaert, W. G. (2006) · International review of cytology · doi:10.1016/s0074-7696(06)54005-7 · Cited by 33
Gleevec: Prototype or Outlier?
Kaelin, W. G. (2004) · Science s STKE · doi:10.1126/stke.2252004pe12 · Cited by 33
Russo, O., Cachard-Chastel, M., Rivière, C., Giner, M., Soulier, J. L., Berthouze, M., Richard, T., Monti, J., Sicsic, S., Lezoualc’h, F., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801327q · Cited by 32
Haesslein, J., & Jullian, N. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393291 · Cited by 31
Tumiatti, V., Rosini, M., Bartolini, M., Cavalli, A., Marucci, G., Andrisano, V., Angeli, P., Banzi, R., Minarini, A., Recanatini, M., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021055+ · Cited by 30
Bate, C., Kempster, S. L., & Williams, A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.02.015 · Cited by 30
Orozco, C., Rı́os, C. D. L., Arias, E., Leon, R. M., Garcı́a, A. G., Marco, J. L., Villarroya, M., & López, M. G. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068189 · Cited by 29
Paz, A., Xie, Q., Greenblatt, H. M., Fu, W., Tang, Y., Silman, I., Qiu, Z., & Sussman, J. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801657v · Cited by 28
Marco, J. L., Rı́os, C. D. L., Carreiras, M. C., Baños, J.-E., Badı́a, A., & Vivas, N. M. (2002) · Archiv der Pharmazie · doi:10.1002/1521-4184(200209)335:7<347::aid-ardp347>3.0.co;2-g · Cited by 28
Alzheimer disease is multifactorial and heterogeneous
Iqbal, K., & Grundke-Iqbal, I. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00191-3 · Cited by 26
Jansson, K., Fristedt, T., Olsson, A., Svensson, B. R., & Jönsson, S. (2006) · The Journal of Organic Chemistry · doi:10.1021/jo052368q · Cited by 23
Recurrent Herpes Simplex Virus Type 2 Meningitis: A Case Report of Mollaret’s Meningitis
Kojima, Y., Hashiguchi, H., Hashimoto, T., Tsuji, S., Shoji, H., & Kazuyama, Y. (2002) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2002.85 · Cited by 21
Polymethylene tetraamine backbone as template for the development of biologically active polyamines
Melchiorre, C., Antonello, A., Banzi, R., Bolognesi, M. L., Minarini, A., Rosini, M., & Tumiatti, V. (2002) · Medicinal Research Reviews · doi:10.1002/med.10029 · Cited by 21
Ezoulin, M. J. M., Li, J., Wu, G., Dong, C., Ombetta, J., Chen, H., Massicot, F., & Heymans, F. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.07.026 · Cited by 20
Ezoulin, J.-M. M., Shao, B.-Y., Xia, Z., Xie, Q., Li, J., Cui, Y., Wang, H., Dong, C., Zhao, Y., Massicot, F., et al. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000455 · Cited by 20
Ros, E., Aleu, J., de Aranda, I. G., Cantı́, C., Pang, Y., Marsal, J., & Solsona, C. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.1.183 · Cited by 20
Endotoxin-Induced Macrophage Gene Expression Depends on Platelet-Activating Factor
Lo, C.-J. (1997) · Archives of Surgery · doi:10.1001/archsurg.1997.01430360088016 · Cited by 17
Texier, L. L., Favre, E., Ronzani, N., et al. (1996) · Journal of Lipid Mediators and Cell Signalling · doi:10.1016/0929-7855(95)00053-4 · Cited by 15
Yamauchi, J., Hirasawa, A., Miyamoto, Y., Kokubu, H., Nishii, H., Okamoto, M., Sugawara, Y., Tsujimoto, G., & Itoh, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00839-2 · Cited by 11
Fasting Decreases the Content of D‐Chiroinositol in Human Skeletal Muscle
Shashkin, P. N., Huang, L. C., Larner, J., Vandenhoff, G. E., & Katz, A. (2002) · Journal of Diabetes Research · doi:10.1080/15604280214280 · Cited by 9
Tetrahydroaminoacridine-induced apoptosis in rat hepatocytes
Fariss, M. W., Mumaw, V. R., & Walton, L. P. (1996) · Toxicology in Vitro · doi:10.1016/0887-2333(96)00034-3 · Cited by 6
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Maternity testing using mitochondrial DNA analysis.
Tsuji, A., Ishiko, A., Hirose, M., Takasaki, T., & Ikeda, N. (2002) · PubMed · doi:10.15017/7183613 · Cited by 1
Cited by
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Metadata
- Authors
- León, R., Garcia, A. G., & Marco‐Contelles, J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2011-07-26
- Volume
- 33
- Issue
- 1
- Pages
- 139-189
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W1940331911
- Cited by
- 440
- References
- 323
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.